1253791-77-3 Usage
Uses
Used in Medicinal Chemistry:
3-(bromomethyl)-6,7-dimethylquinoxalin-2-ol is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its unique structure and reactivity. Its bromomethyl group can be utilized in organic synthesis for the formation of new carbon-carbon bonds, which is crucial in the development of novel therapeutic agents.
Used in Drug Development:
In the pharmaceutical industry, 3-(bromomethyl)-6,7-dimethylquinoxalin-2-ol is used as a lead compound for the discovery of new drugs. Its potential biological activities and interactions with biological targets make it a valuable candidate for further optimization and development into effective medications.
Used in Research and Development:
3-(bromomethyl)-6,7-dimethylquinoxalin-2-ol serves as a valuable tool in academic and industrial research settings. It is used to study the structure-activity relationships of quinoxaline derivatives and to investigate their potential applications in various therapeutic areas. 3-(bromomethyl)-6,7-dimethylquinoxalin-2-ol can also be employed in the design and synthesis of new quinoxaline-based drugs with improved pharmacological profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1253791-77-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,3,7,9 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1253791-77:
(9*1)+(8*2)+(7*5)+(6*3)+(5*7)+(4*9)+(3*1)+(2*7)+(1*7)=173
173 % 10 = 3
So 1253791-77-3 is a valid CAS Registry Number.
1253791-77-3Relevant academic research and scientific papers
BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS
-
Page/Page column 106, (2011/02/24)
The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
